Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production

Immunology

Volumn 125, Issue 2, 2008, Pages 184-196

  Postól, Edilberto ^a   Meyer, André ^b   Cardillo, Fabíola ^b   De Alencar, Raquel ^a   Pessina, Daniel ^b   Nihei, Jorge ^b   Mariano, Mário ^c   Mengel, José ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

BAFF BLyS; Fc receptor; Interleukin 16; Natural killer T cells; Systemic lupus erythematosus; Toll like receptor

Indexed keywords

B CELL ACTIVATING FACTOR; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 16; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NK1.1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLOMERULONEPHRITIS; IN VITRO STUDY; LUPUS LIKE SYNDROME; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 51249085158     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02835.x     Document Type: Article

References (53)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996 85:303 6.
2. O'Keefe TL, Datta SK, Imanishi-Kari T. Cationic residues in pathogenic anti-DNA autoantibodies arise by mutations of a germ-line gene that belongs to a large VH gene subfamily. Eur J Immunol 1992 22:619 24.
3. Hahn BH. Antibodies to DNA. N Engl J Med 1998 338:1359 68.
4. Abedi-Valugerdi M, Hansson M, Moller G. Genetic control of resistance to mercury-induced immune/autoimmune activation. Scand J Immunol 2001 54:190 7.
5. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006 203:553 61.
6. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003 112:1211 22.
7. Wofsy D, Chiang NY, Greenspan JS, Ermak TH. Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune disease. J Autoimmun 1988 1:415 31.
8. Sharabi A, Azulai H, Sthoeger ZM, Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 2007 121:248 57.
9. 1 mice. J Immunol 2005 175:763 70.
10. Yang JQ, Chun T, Liu H, Hong S, Bui H, Van Kaer L, Wang CR, Singh RR. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004 34:1723 32.
11. Sireci G, Russo D, Dieli F et al. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur J Immunol 2007 37:425 33.
12. Sieling PA, Porcelli SA, Duong BT, Spada F, Bloom BR, Diamond B, Hahn BH. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 2000 165:5338 44.
13. Zeng D, Lee MK, Tung J, Brendolan A, Strober S. Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol 2000 164:5000 4.
14. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997 15:535 62.
15. Park SH, Chiu YH, Jayawardena J, Roark J, Kavita U, Bendelac A. Innate and adaptive functions of the CD1 pathway of antigen presentation. Semin Immunol 1998 10:391 8.
16. Mieza MA, Itoh T, Cui JQ et al. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996 156:4035 40.
17. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 2003 171:4439 46.
18. Yang JQ, Wen X, Liu H, Folayan G, Dong X, Zhou M, Van Kaer L, Singh RR. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum 2007 56:1219 33.
19. Nomizo A, Postol E, de Alencar R, Cardillo F, Mengel J. Natural killer T cells are required for the development of a superantigen-driven T helper type 2 immune response in mice. Immunology 2005 116:233 44.
20. Nomizo A, Cardillo F, Postol E, de Carvalho LP, Mengel J. V gamma 1 gammadelta T cells regulate type-1/type-2 immune responses and participate in the resistance to infection and development of heart inflammation in Trypanosoma cruzi-infected BALB/c mice. Microbes Infect 2006 8:880 8.
21. Carneiro CR, Lopes JD, Brentani MM. Carcinoembryonic antigen (CEA): production of immunoprecipitating monoclonal antibodies and development of an enzyme immunoassay. Hybridoma 1987 6:689 92.
22. Soares NM, Santiago MB, Pontes deCarvalho LC. An improved anti-C3/IgG ELISA for quantification of soluble immune complexes. J Immunol Methods 2001 249:199 205.
23. Aguiar PH, Borges dos Santos RR, Larangeira DF et al. A novel monoclonal antibody against canine monocytes/macrophages. Hybrid Hybridomics 2004 23:250 7.
24. Melchers F. Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 2003 62 (Suppl. 2 ii25 7.
25. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 2002 11:181 5.
26. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 1998 37:1334 7.
27. RR EB, De Lorenzo BH, Xander P, Godoy LC, Lopes JD, da Silva NP, Sampaio SC, Mariano M. Role of distinct immune components in the radiation-induced abrogation of systemic lupus erythematosus development in mice. Lupus 2007 16:947 54.
28. Bosello S, Pers JO, Rochas C et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 2007 20:1 8.
29. Noelle RJ, Erickson LD. Determinations of B cell fate in immunity and autoimmunity. Curr Dir Autoimmun 2005 8:1 24.
30. Morimoto S, Nakano S, Watanabe T et al. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 2007 46:1083 6.
31. Lopes-Carvalho T, Kearney JF. Development and selection of marginal zone B cells. Immunol Rev 2004 197:192 205.
32. Lopes-Carvalho T, Kearney JF. Marginal zone B cell physiology and disease. Curr Dir Autoimmun 2005 8:91 123.
33. Lopes-Carvalho T, Foote J, Kearney JF. Marginal zone B cells in lymphocyte activation and regulation. Curr Opin Immunol 2005 17:244 50.
34. Chu VT, Enghard P, Riemekasten G, Berek C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol 2007 179:5947 57.
35. Sumegi A, Antal-Szalmas P, Aleksza M, Kovacs I, Sipka S, Zeher M, Kiss E, Szegedi G. Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus. Clin Immunol 2005 117:271 9.
36. Gao B, Wang Y, Tsan MF. The heat sensitivity of cytokine-inducing effect of lipopolysaccharide. J Leukoc Biol 2006 80:359 66.
37. Augener W, Grey HM. Studies on the mechanism of heat aggregation of human gamma-G. J Immunol 1970 105:1024 30.
38. Yoshimoto K, Takahashi Y, Ogasawara M, Setoyama Y, Suzuki K, Tsuzaka K, Abe T, Takeuchi T. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. Int Immunol 2006 18:1189 96.
39. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999 190:1697 710.
40. Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 2005 6:99 106.
41. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005 307:590 3.
42. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005 23:41 51.
43. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997 100:1059 70.
44. 1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987 166:798 803.
45. McGhee JR, Kunisawa J, Kiyono H. Gut lymphocyte migration: we are halfway 'home'. Trends Immunol 2007 28:150 3.
46. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005 115:2914 23.
47. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 313:670 3.
48. Takahashi T, Strober S. Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur J Immunol 2008 38:156 65.
49. 1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann Rheum Dis 2008 67:154 61.
50. Akadegawa K, Ishikawa S, Sato T et al. Breakdown of mucosal immunity in the gut and resultant systemic sensitization by oral antigens in a murine model for systemic lupus erythematosus. J Immunol 2005 174:5499 506.
51. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 12:1365 71.
52. Uehori J, Matsumoto M, Tsuji S et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan. Infect Immun 2003 71:4238 49.
53. Mullarkey M, Rose JR, Bristol J et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003 304:1093 102.